{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:59Z","timestamp":1786981559693,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Glioblastoma is the most common and the most aggressive malignant primary brain tumor. The diagnosis is made by histopathological analysis following stereotactic biopsy or tumor resection. However, rapid diagnostic clarity is often required before histology becomes available. Glial fibrillary acidic protein (GFAP) has been studied as a blood biomarker for glioblastoma using conventional immunoassays. The aim of this study was to test the diagnostic value of a GFAP point-of-care device to differentiate glioblastoma from other brain tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients admitted to our hospital with a newly diagnosed intracranial lesion suspicious for a brain tumor were enrolled prospectively. Blood samples were collected prior to diagnostic and therapeutic procedures. Plasma GFAP measurements were performed using the TBI plasma test on the i-STAT Alinity\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (Abbott) device. The gold standard was the final histopathological diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We prospectively enrolled 101 patients (mean age 63\u2009\u00b1\u200917 years, 44.6% female). GFAP plasma levels were significantly higher in patients with glioblastoma (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200937; median 610 pg\/mL [interquartile range 263.5\u20131877.5]) compared to other tumors (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200964; 81.5 pg\/mL [40.3\u2013197.3];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A cut-off point of 191 pg\/mL revealed a sensitivity of 84% and a specificity of 75% for diagnosing glioblastoma. A GFAP plasma concentration of &gt;\u20091000 pg\/ml was indicative of glioblastoma with a specificity of 95% and a positive predictive value (PPV) of 82%. Excluding lymphomas further increased the specificity to 96% and PPV to 93%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GFAP measurements using a point-of-care device indicate glioblastoma with high diagnostic accuracy. GFAP testing has the potential to streamline the work-up of brain tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05479-6","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:10:51Z","timestamp":1772269851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective evaluation of GFAP point-of-care testing for rapid diagnosis of glioblastoma"],"prefix":"10.1007","volume":"177","author":[{"given":"Kristaps","family":"Blums","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Love-Preet","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ntenis","family":"Nerntengian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Zylyftari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wehinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sakowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Meckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansj\u00f6rg","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Foerch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"5479_CR1","doi-asserted-by":"publisher","unstructured":"Price M, Neff C, Nagarajan N, Kruchko C, Waite KA, Cioffi G, Cordeiro BB, Willmarth N, Penas-Prado M, Gilbert MR, Armstrong TS, Barnholtz-Sloan JS, Ostrom QT (2024) CBTRUS statistical report: American brain tumor association & NCI neuro-oncology branch adolescent and young adult primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020. Neuro-Oncology 26:iii1-iii53 https:\/\/doi.org\/10.1093\/neuonc\/noae047","DOI":"10.1093\/neuonc\/noae047"},{"key":"5479_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/WCO.0000000000000950","volume":"34","author":"M Smits","year":"2021","unstructured":"Smits M (2021) Update on neuroimaging in brain tumours. Curr Opin Neurol 34:497\u2013504. https:\/\/doi.org\/10.1097\/WCO.0000000000000950","journal-title":"Curr Opin Neurol"},{"key":"5479_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1227\/01.Neu.0000148899.39020.87","volume":"56","author":"J Tilgner","year":"2005","unstructured":"Tilgner J, Herr M, Ostertag C, Volk B (2005) Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis\u2014influence of clinical factors. Neurosurgery 56:257\u2013265. https:\/\/doi.org\/10.1227\/01.Neu.0000148899.39020.87","journal-title":"Neurosurgery"},{"key":"5479_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1750-3639.1994.tb00837.x","volume":"4","author":"RE McLendon","year":"1994","unstructured":"McLendon RE, Bigner DD (1994) Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathol 4:221\u2013228. https:\/\/doi.org\/10.1111\/j.1750-3639.1994.tb00837.x","journal-title":"Brain Pathol"},{"key":"5479_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.brainres.2007.04.070","volume":"1158","author":"DK Cullen","year":"2007","unstructured":"Cullen DK, Simon CM, LaPlaca MC (2007) Strain rate-dependent induction of reactive astrogliosis and cell death in three-dimensional neuronal-astrocytic co-cultures. Brain Res 1158:103\u2013115. https:\/\/doi.org\/10.1016\/j.brainres.2007.04.070","journal-title":"Brain Res"},{"key":"5479_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D\u2019Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H (2022) Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Reviews Neurol 18:158\u2013172. https:\/\/doi.org\/10.1038\/s41582-021-00616-3","journal-title":"Nat Reviews Neurol"},{"key":"5479_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11060-018-2898-1","volume":"139","author":"P Baumgarten","year":"2018","unstructured":"Baumgarten P, Quick-Weller J, Gessler F, Wagner M, Tichy J, Forster MT, Foerch C, Seifert V, Mittelbronn M, Senft C (2018) Pre- and early postoperative GFAP serum levels in glioma and brain metastases. J Neurooncol 139:541\u2013546. https:\/\/doi.org\/10.1007\/s11060-018-2898-1","journal-title":"J Neurooncol"},{"key":"5479_CR8","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1002\/cncr.28949","volume":"120","author":"J Gallego Perez-Larraya","year":"2014","unstructured":"Gallego Perez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson M, Hoang-Xuan K, Delattre JY, Mallet A (2014) Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer 120:3972\u20133980. https:\/\/doi.org\/10.1002\/cncr.28949","journal-title":"Cancer"},{"key":"5479_CR9","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/brain\/awm263","volume":"130","author":"CS Jung","year":"2007","unstructured":"Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336\u20133341. https:\/\/doi.org\/10.1093\/brain\/awm263","journal-title":"Brain"},{"key":"5479_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11060-015-1829-7","volume":"124","author":"A Kiviniemi","year":"2015","unstructured":"Kiviniemi A, Gardberg M, Frantzen J, Parkkola R, Vuorinen V, Pesola M, Minn H (2015) Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival. J Neurooncol 124:237\u2013245. https:\/\/doi.org\/10.1007\/s11060-015-1829-7","journal-title":"J Neurooncol"},{"key":"5479_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10517-020-04741-9","volume":"168","author":"NV Lyubimova","year":"2020","unstructured":"Lyubimova NV, Timofeev YS, Mitrofanov AA, Bekyashev AK, Goncharova ZA, Kushlinskii NE (2020) Glial fibrillary acidic protein in the diagnosis and prognosis of malignant glial tumors. Bull Exp Biol Med 168:503\u2013506. https:\/\/doi.org\/10.1007\/s10517-020-04741-9","journal-title":"Bull Exp Biol Med"},{"key":"5479_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11060-015-1978-8","volume":"126","author":"J Tichy","year":"2016","unstructured":"Tichy J, Spechtmeyer S, Mittelbronn M, Hattingen E, Rieger J, Senft C, Foerch C (2016) Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol 126:361\u2013369. https:\/\/doi.org\/10.1007\/s11060-015-1978-8","journal-title":"J Neurooncol"},{"key":"5479_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11060-017-2565-y","volume":"135","author":"JM Vietheer","year":"2017","unstructured":"Vietheer JM, Rieger J, Wagner M, Senft C, Tichy J, Foerch C (2017) Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma. J Neurooncol 135:193\u2013199. https:\/\/doi.org\/10.1007\/s11060-017-2565-y","journal-title":"J Neurooncol"},{"key":"5479_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.25259\/SNI_889_2022","volume":"13","author":"N Yadav","year":"2022","unstructured":"Yadav N, Mishra K, B CA, Singh D, Subberwal M (2022) Clinical utility of serum glial fibrillary acidic protein in glial neoplasm. Surg Neurol Int 13:601. https:\/\/doi.org\/10.25259\/SNI_889_2022","journal-title":"Surg Neurol Int"},{"key":"5479_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1354750X.2021.2006313","volume":"27","author":"JV van Asperen","year":"2022","unstructured":"van Asperen JV, Fedorushkova DM, Robe P, Hol EM (2022) Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis. Biomark 27:1\u201312. https:\/\/doi.org\/10.1080\/1354750X.2021.2006313","journal-title":"Biomark"},{"key":"5479_CR16","unstructured":"(FDA) FaDA (2022) i-STAT TBI plasma cartridge with the i-STAT alinity system. FDA, 10903 New Hampshire Avenue Silver Spring, MD 20993-0002. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K201778.pdf"},{"key":"5479_CR17","doi-asserted-by":"publisher","unstructured":"FloresAP, Sanchez VC, Roda JM, Cerdan S, Barrios AJ, Utrilla C, Royo C, Gonzalez MLG (2020) Assessment of pre-operative measurements of tumor size by MRI methods as survival predictors in wild type IDH glioblastoma. Front Oncol 10:1662. https:\/\/doi.org\/10.3389\/fonc.2020.01662","DOI":"10.3389\/fonc.2020.01662"},{"key":"5479_CR18","doi-asserted-by":"publisher","unstructured":"RanaM, Modrow D, Keuchel J, Chui C, Rana M, Wagner M, Gellrich NC (2015) Development and evaluation of an automatic tumor segmentation tool: a comparison between automatic, semi-automatic and manual segmentation of mandibular odontogenic cysts and tumors. J Craniomaxillofac Surg 43(3):355-359. https:\/\/doi.org\/10.1016\/j.jcms.2014.12.005","DOI":"10.1016\/j.jcms.2014.12.005"},{"key":"5479_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12672-024-01266-9","volume":"15","author":"SJ Muller","year":"2024","unstructured":"Muller SJ, Khadhraoui E, Henkes H, Ernst M, Rohde V, Schatlo B, Malinova V (2024) Differentiation between multifocal CNS lymphoma and glioblastoma based on MRI criteria. Discov Oncol 15:397. https:\/\/doi.org\/10.1007\/s12672-024-01266-9","journal-title":"Discov Oncol"},{"key":"5479_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0165-5728(85)80063-1","volume":"8","author":"LF Eng","year":"1985","unstructured":"Eng LF (1985) Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 8:203\u2013214. https:\/\/doi.org\/10.1016\/s0165-5728(85)80063-1","journal-title":"J Neuroimmunol"},{"key":"5479_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1023\/a:1007677003387","volume":"25","author":"LF Eng","year":"2000","unstructured":"Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969\u20132000). Neurochem Res 25:1439\u20131451. https:\/\/doi.org\/10.1023\/a:1007677003387","journal-title":"Neurochem Res"},{"key":"5479_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF00165169","volume":"3","author":"WK Yung","year":"1985","unstructured":"Yung WK, Luna M, Borit A (1985) Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol 3:35\u201338. https:\/\/doi.org\/10.1007\/BF00165169","journal-title":"J Neurooncol"},{"key":"5479_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1600-0404.2007.00889.x","volume":"116","author":"T Brommeland","year":"2007","unstructured":"Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V (2007) Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 116:380\u2013384. https:\/\/doi.org\/10.1111\/j.1600-0404.2007.00889.x","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"5479_CR24","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/foc.2006.21.5.3","volume":"21","author":"DL Commins","year":"2006","unstructured":"Commins DL (2006) Pathology of primary central nervous system lymphoma. Neurosurg Focus 21(5):E2. https:\/\/doi.org\/10.3171\/foc.2006.21.5.3","journal-title":"Neurosurg Focus"},{"issue":"6","key":"5479_CR25","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/diagnostics13061046","volume":"13","author":"OA Orzan","year":"2023","unstructured":"Orzan OA, Giurc\u0103neanu C, Dima B, Dima MB, Ion A, B\u0103l\u0103ceanu B, Ni\u021bipir C, Tudose I, Nicolae CA, Doroban\u021bu AM (2023) Cutaneous melanoma and glioblastoma multiforme association-case presentation and literature review. Diagn (Basel) 13(6):1046. https:\/\/doi.org\/10.3390\/diagnostics13061046","journal-title":"Diagn (Basel)"},{"issue":"2","key":"5479_CR26","doi-asserted-by":"publisher","first-page":"e213823","DOI":"10.1212\/WNL.0000000000213823","volume":"105","author":"LP Kalra","year":"2025","unstructured":"Kalra LP, Zylyftari S, Blums K, Barthelmes S, Baum H, Meckel S, Heilgeist A, Luger S, Foerch C (2025) Rapid diagnosis of intracerebral hemorrhage in patients with acute stroke by measuring prehospital GFAP levels on a point-of-care device (DETECT). Neurol 105(2):e213823. https:\/\/doi.org\/10.1212\/WNL.0000000000213823","journal-title":"Neurol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05479-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:05:42Z","timestamp":1781636742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05479-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5479"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05479-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with national law, institutional ethical standards, and the Declaration of Helsinki. The study protocol was approved by the ethics committee of \u00c4rztekammer of Baden-W\u00fcrttemberg (case number F-2022-138). Written consent was acquired from all patients or legal representatives before inclusion in the study and further testing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients consented to the publishing of the study results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}